1-5 of 5
Hanno R. Hock, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Philip C. Amrein, MD, Karen K. Ballen, MD, Kristen E. Stevenson, MS, Traci M. Blonquist, MS, Andrew M. Brunner, Gabriela S. Hobbs, MD, Hanno R. Hock, MD PhD, Steven L. McAfee, MD, Jenna A. Moran, NP, Meghan Bergeron, NP, Julia E. Foster, NP, Christina Bertoli, NP, Kristin McGregor, Molly Macrae, Meghan Burke, Tanya T. Behnan, BS, Tina T. Som, RN, Aura Y. Ramos, RN, Megan K. Vartanian, RN, Jennifer Lombardi Story, Christine Connolly, Timothy A. Graubert, MD, Donna S. Neuberg, ScD, Amir T. Fathi
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-139661
Published: 2020
Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Philip C. Amrein, MD, Eyal C. Attar, MD, Geoffrey Fell, Traci M. Blonquist, MS, Andrew M. Brunner, Gabriela S. Hobbs, MD, Hanno R. Hock, MD PhD, Steven L. McAfee, MD, Rupa Narayan, MD, Jenna A. Moran, NP, Meghan Bergeron, NP, Julia E. Foster, NP, Christina Bertoli, NP, Kristin McGregor, Molly Macrae, Meghan Burke, Tanya T. Behnan, BS, Tina T. Som, RN, Aura Y. Ramos, RN, Megan K. Vartanian, RN, Jennifer Lombardi Story, Donna S. Neuberg, ScD, Amir T. Fathi
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-140584
Published: 2020
Journal Articles

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

Chi-Joan How, MD, Siyang Ren, Jennifer Lombardi Story, Meghan Bergeron, NP, Julia E. Foster, NP, Philip C. Amrein, MD, Andrew M. Brunner, Amir T. Fathi, Hanno R. Hock, MD PhD, Jenna A. Moran, NP, Rupa Narayan, Donna S. Neuberg, ScD, Aura Y. Ramos, RN, Tina T. Som, RN, Megan Vartanian, RN, Yi-Bin Chen, MD, Gabriela S. Hobbs, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-140278
Published: 2020
Journal Articles

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2 -Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation

Amir T. Fathi, Shuli Li, PhD, Robert J. Soiffer, MD, Mark Levis, MD PhD, Alice S. Mims, MD, Steven M Devine, MD, Zachariah Defilipp, MD, Areej El-Jawahri, MD, Steven L. McAfee, MD, Thomas R. Spitzer, MD, Matthew J Frigault, MD MSc, Bimalangshu R. Dey, MD, Philip C. Amrein, MD, Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Hanno R. Hock, MD PhD, Rupa Narayan, Laura W. Knight, Devon Kelley, AJ S. Bottoms, Jami L. Brown, MS, Candice J. Del Rio, RN, MS, Julie E. Vanderklish, ANP, Colleen Danielson, NP, Meredith L. Saylor, NP, Chrisa L. Hunnewell, Lindsey H. Perry, Jonathan L. Wahl, Elayne Breton, Vincent T. Ho, MD, Yi-Bin Chen, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-140176
Published: 2020
Journal Articles

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, Alexander E. Perl, MD, Mark Levis, MD PhD, Catherine C. Smith, MD, Andrew M. Brunner, Koichi Takahashi, MD PhD, Philip C. Amrein, MD, Hanno R. Hock, MD PhD, Gabriela S. Hobbs, MD, Rupa Narayan, Jenna A. Moran, NP, Meghan Bergeron, NP, Julia E. Foster, NP, Naval Daver, MD, Courtney D. DiNardo, MD MSCE
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-140118
Published: 2020